MarketCap
Facebook
X
Telegram
Artelo Biosciences ROE Ratio | ARTL
Annual ROE Ratio Artelo Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1012.5 | -343.93 | -79.04 | -51.97 | -14.85 | -120.14 | -39.77 | 1736.25 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1736.25 | -343.93 | 262.38 |
Quarterly ROE Ratio Artelo Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 594.62 | 313.84 | 358.18 | 340.38 | -185.84 | -440.97 | -77.16 | -93.96 | -86.0 | -64.96 | -38.92 | -49.56 | -43.03 | -40.83 | -28.53 | -43.39 | -52.3 | -59.57 | -64.7 | -74.33 | -70.62 | -68.93 | -72.02 | -73.86 | -84.33 | -94.81 | -105.28 | 38.24 | 181.76 | 325.29 | 468.81 | 257.37 | 118.3 | -16.64 | -228.08 | 13.48 | 71.95 | 158.64 | -2015.23 | -2162.55 | -2229.57 | -2282.52 | -2451.02 | -283.0 | -319.63 | -99.54 | - | -100.1 | -103.65 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 594.62 | -2451.02 | -230.51 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M |  Canada |
 |
Precision BioSciences
DTIL
|
-49.57 | $ 10.62 | 7.6 % | $ 136 M |  USA |
 |
AIM ImmunoTech
AIM
|
142.68 | $ 0.16 | 4.41 % | $ 259 K | USA |
 |
Ascendis Pharma A/S
ASND
|
140.05 | $ 256.91 | 1.37 % | $ 15.6 B |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
14.43 | $ 67.32 | -3.3 % | $ 1.35 B | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-432.56 | $ 1.42 | 9.23 % | $ 44.3 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.29 | 2.38 % | $ 343 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
35.13 | $ 74.28 | 0.01 % | $ 14.2 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-221.45 | $ 7.69 | 0.72 % | $ 1.61 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-35.9 | $ 3.6 | 3.45 % | $ 249 M | Britain |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 0.77 | 2.9 % | $ 90.2 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 25.59 | -5.24 % | $ 3.26 B | USA |
 |
Cellectis S.A.
CLLS
|
-89.05 | $ 1.09 | 5.83 % | $ 109 M |  France |
 |
BeyondSpring
BYSI
|
3.13 | $ 0.61 | -3.32 % | $ 25.1 M | USA |
 |
Alkermes plc
ALKS
|
13.29 | $ 45.88 | 3.01 % | $ 7.56 B |  Irlanda |
 |
Altimmune
ALT
|
-39.17 | $ 2.09 | 6.09 % | $ 184 M | USA |
 |
Cardiff Oncology
CRDF
|
-0.1 | $ 0.8 | 5.3 % | $ 53.5 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-58.83 | $ 0.55 | -1.2 % | $ 6.09 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 10.35 | 10.52 % | $ 283 M |  Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.35 | $ 58.16 | 1.22 % | $ 7.78 B | USA |
 |
Incyte Corporation
INCY
|
24.9 | $ 119.79 | 1.51 % | $ 23.4 B | USA |
 |
Atara Biotherapeutics
ATRA
|
-84.9 | $ 7.81 | -1.88 % | $ 98 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
49.4 | $ 16.32 | 0.68 % | $ 2.19 B | Canada |
 |
Cullinan Management
CGEM
|
-53.8 | $ 11.37 | 5.28 % | $ 685 M | USA |
 |
BioNTech SE
BNTX
|
-5.91 | $ 87.46 | 1.86 % | $ 21.1 B |  Germany |
 |
Collegium Pharmaceutical
COLL
|
20.88 | $ 24.19 | -3.86 % | $ 766 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-53.24 | $ 3.07 | 7.34 % | $ 40.9 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
63.85 | $ 1.26 | -0.79 % | $ 57.6 M | Israel |
 |
AnaptysBio
ANAB
|
1237.56 | $ 46.46 | 1.92 % | $ 1.35 B | USA |
 |
Assembly Biosciences
ASMB
|
-2.96 | $ 20.43 | 2.17 % | $ 229 M | USA |
 |
Adagene
ADAG
|
-49.82 | $ 1.99 | -1.73 % | $ 117 M |  China |
 |
Benitec Biopharma
BNTC
|
-25.73 | $ 9.51 | 10.07 % | $ 443 M | USA |
 |
Denali Therapeutics
DNLI
|
-50.56 | $ 20.09 | 1.88 % | $ 3.47 B | USA |
 |
Amarin Corporation plc
AMRN
|
-8.45 | $ 11.55 | -0.2 % | $ 4.79 B | Irlanda |
 |
Editas Medicine
EDIT
|
-586.56 | $ 2.57 | 0.59 % | $ 228 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-34.62 | $ 29.4 | 4.0 % | $ 1.7 B | USA |
 |
Cue Biopharma
CUE
|
-100.64 | $ 18.93 | 5.11 % | $ 1.79 B | USA |
 |
Equillium
EQ
|
-78.32 | $ 1.54 | 15.79 % | $ 88.2 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
19932.98 | $ 1.73 | 4.22 % | $ 98.4 M | USA |
 |
Pliant Therapeutics
PLRX
|
82.39 | $ 0.81 | -0.12 % | $ 49.7 M | USA |
 |
Abeona Therapeutics
ABEO
|
-44.71 | $ 4.18 | 6.78 % | $ 221 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
-9.17 | $ 4.36 | 8.19 % | $ 706 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
31.86 | $ 21.22 | -0.09 % | $ 3.57 B | USA |
 |
PainReform Ltd.
PRFX
|
-58.78 | $ 0.85 | 11.62 % | $ 551 K | Israel |
 |
Jazz Pharmaceuticals plc
JAZZ
|
-8.25 | $ 235.01 | 3.38 % | $ 14.3 B | Irlanda |
 |
Atossa Therapeutics
ATOS
|
-88.35 | $ 2.14 | 5.94 % | $ 18.4 M | USA |
 |
Liquidia Corporation
LQDA
|
-154.03 | $ 44.53 | 0.08 % | $ 3.83 B | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
-119.12 | - | -7.31 % | $ 49 M | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
-31.81 | - | - | $ 1.77 B | USA |
 |
ADC Therapeutics SA
ADCT
|
76.75 | $ 1.59 | -2.16 % | $ 202 M |  Schweiz |